Merck to partner with 'somatic genomics' startup Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 24 March, 2026

Every year, John Carroll sizes up the top 15 global pharma pipelines — then brings the findings live with the R&D chiefs shaping them. What's in, what's out, and what's next for 2026? Register now.

presented by Fu­ji­film ex­pands glob­al life sci­ences foot­print through large-scale bio­man­u­fac­tur­ing in­vest­ments

news Gilead bets $1.68B upfront on Ouro Medicines’ autoimmune program, with Galapagos expected to pitch in Merck partners with Flagship's 'somatic genomics' startup to search for clues to IBD Apnimed set to exit sleep disorder joint venture with Shionogi for $100M upfront UK biotech co-founded by Nobel laureate secures $86M for antibody program

Mar 24 11:30 am ET From structure to selectivity: Federated AI for collaborative binding affinity prediction sponsored by Rhino Federated Computing

Head of Regulatory Strategy TCG stealth clinic-ready newco Boston, MA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.

ENDPOINTS PHARMA FDA posts photos of Indian drugmaking facility cited in warning letter Novartis to invest $480M in China following AstraZeneca and Lilly pledges WuXi AppTec’s bet on the US pays off as revenues dip elsewhere

in case you missed it 1. Aurinia's CEO and C-suite are out as investor Kevin Tang consolidates control 2. Former Acorda CEO Ron Cohen emerges at Parkinson’s cell therapy biotech Oryon 3. A California startup wins $180M in support as Sanofi rebuilds presence in T cell engagers 4. Lack of cases hampers Pfizer’s Phase 3 Lyme disease vaccine trial 5. Apogee’s Phase 2 data show its eczema drug could have the convenience edge over Dupixent, Ebglyss 6. Arikayce could become Insmed’s second blockbuster following late-stage win in lung infection 7. News Briefing Dizal's first-line lung cancer data; Sanofi expands in China 8.